Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Downloaded from https://aidsinfo.nih.gov/guidelines on 9/2/2018

Visit the AIDSiNfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Transmission and Mode of Delivery

Panel’s Recommendations

- Scheduled cesarean delivery at 38 weeks’ gestation to minimize perinatal transmission of HIV is recommended for women with HIV RNA levels >1,000 copies/mL or unknown HIV levels near the time of delivery, irrespective of administration of antepartum antiretroviral therapy (ART) (AII).
- Scheduled cesarean delivery performed solely for prevention of perinatal transmission in women receiving ART with HIV RNA ≤1,000 copies/mL is not routinely recommended due to the low rate of perinatal transmission in this group (AII).
- In women with HIV RNA levels ≤1000 copies/mL, if scheduled cesarean delivery or induction is indicated, it should be performed at the standard time for obstetrical indications (AII).
- In women with an HIV RNA >1,000 copies/mL or unknown HIV RNA level who present in spontaneous labor or with ruptured membranes, there is insufficient evidence to determine whether cesarean reduces the risk of perinatal HIV transmission. Management of women originally scheduled for cesarean delivery because of HIV infection who present in labor must be individualized at the time of presentation (BII). In these circumstances, consultation with an expert in perinatal HIV (e.g., telephone consultation with the National Perinatal HIV/AIDS Clinical Consultation Center at (888) 448-8765) may be helpful in rapidly developing an individualized delivery plan.
- In women on ART with HIV RNA ≤1,000 copies/mL, duration of ruptured membranes is not associated with an increased risk of perinatal transmission, and vaginal delivery is recommended (BII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Basis for Current Recommendations

Scheduled cesarean delivery, defined as cesarean delivery performed before the onset of labor and before rupture of membranes, is recommended for prevention of perinatal transmission of HIV in women with HIV RNA levels >1,000 copies/mL near delivery and for women with unknown HIV RNA levels.

This recommendation is based on findings from a multicenter, randomized clinical trial and from a large individual patient data meta-analysis. These two studies were conducted at a time when the majority of women with HIV received no antiretroviral (ARV) drugs or zidovudine as a single drug and before the availability of viral load information. Study results have since been extrapolated to make current recommendations about the mode of delivery in an era when antiretroviral therapy (ART) during pregnancy is recommended and viral load information is readily available.

HIV RNA Level of >1000 copies/mL as a Threshold for Recommendation of Scheduled Cesarean Delivery

The American Congress of Obstetricians and Gynecologists (ACOG) recommends that women with HIV RNA >1,000 copies/mL be counseled regarding the potential benefits of scheduled cesarean delivery. Initially, the threshold of 1,000 copies/mL was based largely on data from the Women and Infants Transmission Study, a large prospective cohort study that reported no HIV transmission among 57 women with HIV RNA levels <1,000 copies/mL. Studies reported since then have demonstrated that HIV transmission can occur in infants born to women with low viral loads.

In an analysis of 957 women with plasma viral loads ≤1,000 copies/mL, cesarean delivery (scheduled or urgent) reduced the risk of HIV transmission when adjusting for potential confounders including receipt of maternal ARV medications (AOR 0.30; P = 0.022); however, zidovudine alone was the regimen primarily used as prophylaxis. Among infants born to 834 women with HIV RNA ≤1,000 copies/mL receiving ARV medications, 8 (1%) were born with HIV. In a report from a comprehensive national surveillance system in the United Kingdom and Ireland, 3 (0.1%) of 2,309 and 12 (1.2%) of 1,023 infants born to women with HIV RNA levels <50 copies/mL and 50 to 999 copies/mL, respectively, were born with HIV, some of which appear to represent in utero transmission.

Some studies demonstrate that transmission can occur even at very low HIV RNA levels. However, given the
low rate of transmission in this group, it is unclear whether scheduled cesarean delivery confers any additional benefit in reducing transmission. Furthermore, there is evidence that complication rates for cesarean deliveries are higher in women with HIV compared with women without HIV.\(^7\) Therefore, decisions about mode of delivery for women receiving ART with HIV RNA levels ≤1,000 copies/mL should be individualized based on discussion between an obstetrician and a pregnant woman. Women should be informed that there is no evidence of benefit for scheduled cesarean delivery performed solely for prevention of perinatal transmission in women receiving ART with HIV RNA ≤1,000 copies/mL and that it is not routinely recommended in this group.

**Scheduled Cesarean Delivery in the Antiretroviral Therapy Era**

In surveillance data from the United Kingdom and Ireland, pregnant women receiving ART (i.e., at least 3 drugs) had transmission rates of about 1%, unadjusted for mode of delivery.\(^6\) Given the low transmission rates achievable with use of maternal ART, the benefit of scheduled cesarean delivery is difficult to evaluate. Both the randomized clinical trial\(^1\) and meta-analysis\(^2\) documenting the benefits of cesarean delivery included mostly women who were receiving either no ARV drugs or zidovudine alone. However, other data partially address this issue.

In a report on births to women with HIV from the United Kingdom and Ireland between 2000 and 2011, perinatal transmission rates in women on ART with HIV RNA<1,000 copies/mL with planned cesarean delivery (13/3814; 0.3%) were not significantly different than those in similar women with planned vaginal delivery (6/2238; 0.3%).\(^8\) Similarly, data from the French Perinatal Cohort showed no difference in transmission rates between vaginal delivery and planned cesarean delivery among women on ART with suppressed viral loads, 0.3% in both. For preterm deliveries with HIV RNA <1,000 copies/mL, transmission rates were slightly higher among planned vaginal deliveries but the numbers were small and the differences were not statistically significant (1/9 [11.1%] vs. 1/17 [5.9%] for HIV RNA 400–1000 copies/mL; 1/39 [2.6%] vs. 1/56 [1.8%] for HIV RNA 50–400 copies/mL; 1/189 [0.5%] vs. 0/143 [0%] for HIV RNA <50 copies/mL, for planned vaginal deliveries and elective cesarean deliveries, respectively).\(^9\) Therefore, no evidence to date suggests any benefit from scheduled cesarean delivery in women who have been receiving ART for several weeks and who have achieved virologic suppression.

When the delivery method selected is scheduled cesarean delivery and the maternal viral load is >1,000 copies/mL, a 1-hour loading dose followed by a continuous intravenous (IV) zidovudine infusion for 2 hours (3 hours total) before scheduled cesarean delivery should be administered. In a study of the pharmacokinetics of IV zidovudine in 28 pregnant women, the ratio of cord blood-to-maternal-zidovudine levels increased significantly in women who received IV zidovudine for 3 to 6 hours compared with <3 hours before delivery (1.0 vs. 0.55, respectively).\(^10\) This suggests that an interval of at least 3 hours may provide adequate time to reach equilibrium across the placenta, although the relationship between specific cord blood zidovudine levels or cord blood-to-maternal-zidovudine levels and efficacy in preventing perinatal transmission of HIV is unknown.

Because unscheduled cesarean delivery is performed for both maternal and fetal indications, when an unscheduled cesarean delivery is indicated in a woman who has a viral load >1,000 copies/mL, consideration can be given to shortening the interval between initiation of IV zidovudine administration and delivery. For example, some experts recommend administering the 1-hour loading dose of IV zidovudine and not waiting to complete additional administration before proceeding with delivery.

**Women Presenting Late in Pregnancy**

Women with HIV who present late in pregnancy and are not receiving ARV drugs may not have HIV RNA results available before delivery. Without current therapy, HIV RNA levels are unlikely to be ≤1,000 copies/mL at baseline. Even if ART was begun immediately, reduction in plasma HIV RNA to undetectable levels may take several weeks, depending on the baseline viral load and kinetics of viral decay for a particular drug regimen.\(^11-13\) In this instance, scheduled cesarean delivery is likely to provide additional benefit in reducing the risk of perinatal transmission of HIV for women, unless viral suppression can be documented before 38 weeks’ gestation. Although some experts would recommend a cesarean delivery in a woman who has been virologically
suppressed for a brief period of time (e.g., less than 2 weeks), many others would support a vaginal delivery in this scenario, as long as the plasma HIV RNA level was <1000 copies/mL by the day of delivery.

**Timing of Scheduled Cesarean Delivery**

For the general obstetric population, ACOG recommends that scheduled cesarean delivery not be performed before 39 weeks’ gestation because of the risk of iatrogenic prematurity. However, in cases of cesarean delivery performed to prevent transmission of HIV, ACOG recommends scheduling cesarean delivery at 38 weeks’ gestation in order to decrease the likelihood of onset of labor or rupture of membranes before delivery.

In all women undergoing repeat cesarean delivery, the risk of any neonatal adverse event—including neonatal death, respiratory complications, hypoglycemia, newborn sepsis, or admission to the neonatal intensive care unit—is 15.3% at 37 weeks, 11.0% at 38 weeks, and 8.0% at 39 weeks. Gestational age should be determined by best obstetrical dating criteria, including last menstrual period and early ultrasound for dating purposes. Amniocentesis to document lung maturity should be avoided when possible in women with HIV and is rarely indicated before scheduled cesarean section for prevention of HIV transmission.

Among 1,194 infants born to mothers with HIV, 9 (1.6%) infants born vaginally had respiratory distress syndrome (RDS) compared with 18 (4.4%) infants born by scheduled cesarean delivery ($P < 0.001$). There was no statistically significant association between mode of delivery and infant RDS in an adjusted model that included infant gestational age and birth weight. Although newborn complications may be increased in planned births <39 weeks’ gestation, the benefits of planned cesarean delivery at 38 weeks are generally thought to outweigh the risks if the procedure is performed for prevention of HIV transmission. When scheduled cesarean delivery is performed in women with HIV with an HIV RNA ≤1,000 copies/mL for an indication other than decreasing HIV transmission, cesarean delivery should be scheduled based on ACOG guidelines for women without HIV.

**Risk of Maternal Complications**

Administration of perioperative antimicrobial prophylaxis is recommended for all women to decrease maternal infectious morbidity associated with cesarean delivery. Most studies have demonstrated that women with HIV have increased rates of postoperative complications, mostly infectious, compared with women without HIV and that risk of complications is related to degree of immunosuppression and the receipt of suppressive ART. Furthermore, a Cochrane review of six studies of women with HIV concluded that urgent cesarean delivery was associated with the highest risk of postpartum morbidity, scheduled cesarean delivery was intermediate in risk, and vaginal delivery had the lowest risk of morbidity. Complication rates in most studies were within the range reported in populations of women without HIV with similar risk factors and not of sufficient frequency or severity to outweigh the potential benefit of reduced perinatal HIV transmission. A recent U.S. study of nationally representative data from a large administrative database demonstrated that (even in the era of ART) infectious complications, surgical trauma, prolonged hospitalization, and in-hospital deaths remain higher among women with HIV compared to women without HIV. The rate of any complication associated with cesarean delivery was 117 per 1,000 deliveries among women with HIV compared with 67 per 1,000 deliveries among women without HIV. Therefore, women with HIV should be counseled regarding the specific risks associated with undergoing cesarean delivery in the setting of HIV infection.

In addition, caution should be exercised in proceeding with a cesarean delivery in circumstances where there is no clear evidence of benefit, especially in younger women who are likely to have additional pregnancies and perhaps multiple cesarean deliveries. Increased risk of abnormal placentation (e.g., placenta previa, placenta accreta, placenta increta, placenta percreta) and intrapartum hemorrhage are associated with increasing numbers of cesarean deliveries. These risks should be considered and discussed with the woman before proceeding with a cesarean delivery.

**Managing Women Who Present in Early Labor or with Ruptured Membranes**

Most studies have shown a similar risk of transmission for cesarean delivery performed for obstetric indications...
after labor and membrane rupture as for vaginal delivery. In one study, the HIV transmission rate was similar in women undergoing emergency cesarean delivery and those delivering vaginally (1.6% vs. 1.9%, respectively). A meta-analysis of women with HIV, most of whom were receiving no ARV drugs or only zidovudine, demonstrated a 2% increased transmission risk for every additional hour of ruptured membranes. However, it is not clear how soon after the onset of labor or the rupture of membranes the benefit of cesarean delivery is lost.

A prospective study of 707 women in Ireland showed that among the 493 women on ART with HIV RNA levels <1,000 copies/mL, no cases of perinatal transmission occurred with membranes ruptured for up to 25 hours. Only a viral load of >10,000 copies/mL was an independent risk factor for perinatal transmission. A meta-analysis of women with HIV, most of whom were receiving no ARV drugs or only zidovudine, demonstrated a 2% increased transmission risk for every additional hour of ruptured membranes, regardless of viral load. Eighty-nine percent had HIV RNA levels <50 copies/mL; among the remaining 11%, 9% had HIV RNA levels 50–399 copies/mL, 1% 400–999 copies/mL, 0.4% 1000–9999 copies/mL, and 0.6% >10,000 copies/mL. Among mother-baby pairs with perinatal transmission and no evidence of in utero transmission, 2 had undetectable HIV RNA levels (<50 copies/ml), one had an HIV RNA level of 50–399 copies/ml, and 2 had levels >10,000 copies/ml. Among term deliveries, median duration of rupture of membranes was 3 hours 30 minutes; 71 (3.4%) had rupture of membranes >24 hours and 24 (1.1%) had rupture of membranes >48 hours. The authors concluded that obstetric care of women on ART at term with ruptured membranes should be “normalized.” Because it is not clear whether cesarean delivery after onset of labor reduces the risk of perinatal HIV transmission, management of women originally scheduled for cesarean delivery who present in labor must be individualized at the time of presentation. In these circumstances, consultation with an expert in perinatal HIV may be helpful. Because the delivery plan in the setting of labor must be made quickly, telephone consultation with a 24-hour, 7-day-a-week hotline (e.g., the National Perinatal HIV/AIDS Clinical Consultation Center (888) 448-8765) may be helpful in rapidly developing an individualized plan.

The woman’s oral ARV drug regimen should be continued, and IV zidovudine initiated (if previously planned) regardless of the mode of delivery.

When membrane rupture occurs before 37 weeks’ gestation, decisions about timing of delivery should be based on best obstetrical practices, considering risks to the infant of prematurity and of HIV transmission. Steroids should be given, if appropriate, to accelerate fetal lung maturity because no data exist to suggest that these recommendations need to be altered for women with HIV. When the decision is made to deliver, route of delivery should be according to obstetrical indications.

Operative Vaginal Delivery

In the past HIV was considered a relative contraindication to operative vaginal delivery with forceps or vacuum, but data from the era of ART had been lacking. Peters et al. reviewed 9,072 deliveries of women living with HIV in the UK between 2008 and 2016, where 80% of women had viral suppression from 2007 through 2011 and 90% from 2012 through 2014. Among the 3,023/3,663 vaginal deliveries with data as to whether forceps/vacuum were used, 249 (8.2%) involved operative delivery (5.6% forceps, 2.4% vacuum, 0.1% both, and 0.2% type not known). Among the 222 infants with known HIV status at 18 months of age, there was 1 case of HIV transmission with multiple possible causes and not enough evidence to confirm intrapartum transmission. The authors concluded that operative delivery is a safe option among women who are virally suppressed.

References


